Naringin inhibits tumor growth and reduces interleukin-6 and tumor necrosis factor α levels in rats with Walker 256 carcinosarcoma

Anticancer Research

Volumn 32, Issue 1, 2012, Pages 129-133

  Camargo, Camila A ^a   Gomes Marcondes, Maria Cristina C ^a   Wutzki, Nathalie C ^a   Aoyama, Hiroshi ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Cachexia; Cancer; Naringin; Survival; Tumor necrosis factor and interleukin 6; Walker 256 carcinosarcoma

Indexed keywords

AURANTIIN; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; TUMOR GROWTH; TUMOR REGRESSION; WALKER CARCINOMA;

ANIMALS; CACHEXIA; CARCINOMA 256, WALKER; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLAVANONES; INTERLEUKIN-6; LIVER; MALE; RATS; RATS, WISTAR; SURVIVAL RATE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84855656512     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. WHO: World Cancer Report 2008. World Health Organization International Agency for Research on Cancer [http://apps.who.int/bookorders/WHP/detart1.jsp? sesslan=1&codlan=1&codcol=76&codcch=26]. 2009.
2. Tisdale MJ: Cancer cachexia. Curr Opin Gastroenterol 26: 146-151, 2009.
3. Argiles JM, Moore-Carrasco R, Fuster G, Busquets S and Lopez-Soriano FJ: Cancer cachexia: the molecular mechanisms. Int J Biochem Cell Biol 35: 405-409, 2003. (Pubitemid 36140062)
4. van Halteren HK, Bongaerts GP and Wagener DJ: Cancer cachexia: what is known about its etiology and what should be the current treatment approach? Anticancer Res 23: 5111-5115, 2003. (Pubitemid 38182133)
5. Martin C, Schaller MD, Lepori M and Liaudet L: Cranial nerve palsies and descending paralysis in a drug abuser resulting from wound botulism. Intensive Care Med 25: 765, 1999. (Pubitemid 29376135)
6. Argiles JM and Lopez-Soriano FJ The role of cytokines in cancer cachexia. Med Res Rev 19: 223-248, 1999. (Pubitemid 29198276)
7. Skipworth RJ, Stewart GD, Dejong CH, Preston T and Fearon KC: Pathophysiology of cancer cachexia: much more than host-tumour interaction? Clin Nutr 26: 667-676, 2007. (Pubitemid 350107710)
8. Seruga B, Zhang H, Bernstein LJ and Tannock IF: Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer 8: 887-899, 2008.
9. Tisdale MJ: Metabolic abnormalities in cachexia and anorexia. Nutrition 16: 1013-1014, 2000.
10. Tisdale MJ: Mechanisms of cancer cachexia. Physiol Rev 89: 381-410, 2009.
11. Argiles JM, Busquets S, Felipe A and Lopez-Soriano FJ: Molecular mechanisms involved in muscle wasting in cancer and ageing: cachexia versus sarcopenia. Int J Biochem Cell Biol 37: 1084-1104, 2005. (Pubitemid 40311748)
12. Tang M, Ogawa K, Asamoto M, Hokaiwado N, Seeni A, Suzuki S, Takahashi S, Tanaka T, Ichikawa K and Shirai T: Protective effects of citrus nobiletin and auraptene in transgenic rats developing adenocarcinoma of the prostate (TRAP) and human prostate carcinoma cells. Cancer Sci 98: 471-477, 2007. (Pubitemid 46566174)
13. Limtrakul P, Phromnoi K, Reuter S, Sung B and Aggarwal BB: A dihydroxy-pentamethoxyflavone from Gardenia obtusifolia suppresses proliferation and promotes apoptosis of tumor cells through modulation of multiple cell signaling pathways. Anticancer Res 30: 3599-3610, 2010.
14. Ribeiro IA and Ribeiro MHL: Naringin and naringenin determination and control in grapefruit juice by a validated HPLC method. Food Control 19: 432-438, 2008. (Pubitemid 47571023)
15. Ye H, Xu HD, Yu CG, Dai YJ, Liu GY, Xu WP and Yuan S: Hydroxylation of naringin by Trichoderma harzianum to dramatically improve its antioxidative activity. Enzyme Microb Tech 45: 282-287, 2009.
16. Han S-S and You I-J: Studies on antimicrobial activities and safety of natural naringin in Korea. Korean Soc Mycol 16: 33-40, 1988.
17. Kaul TN, Middleton E Jr. and Ogra PL: Antiviral effect of flavonoids on human viruses. J Med Virol 15: 71-79, 1985. (Pubitemid 15184364)
18. Martin MJ, Marhuenda E, Perez-Guerrero C and Franco JM: Antiulcer effect of naringin on gastric lesions induced by ethanol in rats. Pharmacology 49: 144-150, 1994. (Pubitemid 24236156)
19. Kanno S, Tomizawa A, Hiura T, Osanai Y, Shouji A, Ujibe M, Ohtake T, Kimura K and Ishikawa M: Inhibitory effects of naringenin on tumor growth in human cancer cell lines and sarcoma S-180-implanted mice. Biol Pharm Bull 28: 527-530, 2005. (Pubitemid 40879982)
20. So FV, Guthrie N, Chambers AF, Moussa M and Carroll KK: Inhibition of human breast cancer cell proliferation and delay of mammary tumorigenesis by flavonoids and citrus juices. Nutr Cancer 26: 167-181, 1996. (Pubitemid 26300196)
21. Le Marchand L, Murphy SP, Hankin JH, Wilkens LR and Kolonel LN: Intake of flavonoids and lung cancer. J Natl Cancer Inst 92: 154-160, 2000. (Pubitemid 30089873)
22. Tomasik P: Chemical and Functional Properties of Food Saccharides. Boca Raton: CRC Press, 2004.
23. Benavente-Garcia O and Castillo J: Update on uses and properties of citrus flavonoids: new findings in anticancer, cardiovascular, and anti-inflammatory activity. J Agric Food Chem 56: 6185-6205, 2008.
24. Kawaguchi K, Kikuchi S, Hasegawa H, Maruyama H, Morita H and Kumazawa Y: Suppression of lipopolysaccharide-induced tumor necrosis factor-release and liver injury in mice by naringin. Eur J Pharmacol 368: 245-250, 1999. (Pubitemid 29117146)
25. Gordon PB, Holen I and Seglen PO: Protection by naringin and some other flavonoids of hepatocytic autophagy and endocytosis against inhibition by okadaic acid. J Biol Chem 270: 5830-5838, 1995.
26. Camargo CA, da Silva ME, da Silva RA, Justo GZ, Gomes-Marcondes MC and Aoyama H: Inhibition of tumor growth by quercetin with increase of survival and prevention of cachexia in Walker 256 tumor-bearing rats. Biochem Biophys Res Commun 406: 638-642, 2011.
27. Vale C, Stewart L and Tierney J: Trends in UK cancer trials: results from the UK Coordinating Committee for Cancer Research National Register of Cancer Trials. Br J Cancer 92: 811-814, 2005. (Pubitemid 40462622)
28. Gomes-Marcondes MC, Honma HN, Areas MA and Cury L: Effect of Walker 256 tumor growth on intestinal absorption of leucine, methionine and glucose in newly weaned and mature rats. Braz J Med Biol Res 31: 1345-1348, 1998. (Pubitemid 128530241)
29. Gomes-Marcondes MC. Influência da gestação sobre o crescimento do câncer e deste sobre o desenvolvimento fetoplacentá rio. Campinas, São Paulo, Brazil: Universidade Estadual de Campinas (UNICAMP), PhD Thesis, 1994.
30. Kaplan EL and Meier P: Nonparametric-estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958.
31. Mantel N Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50: 163-170, 1966.
32. Cox DR: Regression models and life-tables. J Roy Stat Soc 34: 187-120, 1972.
33. Kawakami M, Pekala PH, Lane MD and Cerami A. Lipoprotein lipase suppression in 3T3-L1 cells by an endotoxin-induced mediator from exudate cells. Proc Natl Acad Sci USA 79: 912-916, 1982. (Pubitemid 12160332)
34. Busquets S, Deans C, Figueras M, Moore-Carrasco R, Lopez-Soriano FJ, Fearon KC and Argiles JM: Apoptosis is present in skeletal muscle of cachectic gastro-intestinal cancer patients. Clin Nutr 26: 614-618, 2007. (Pubitemid 47618326)
35. Inui A: Cancer anorexia-cachexia syndrome: are neuropeptides the key? Cancer Res 59: 4493-4501, 1999.
36. Samuels SE, Knowles AL, Tilignac T, Debiton E, Madelmont JC and Attaix D: Protein metabolism in the small intestine during cancer cachexia and chemotherapy in mice. Cancer Res 60: 4968-4974, 2000.